Join Growin Stock Community!

景凱6549.TW Overview

TW StockBiotech. & Medical
(No presentation for 6549)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

景凱（6549）Overall Performance

景凱（6549）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

景凱（6549） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

景凱（6549）Key Information

景凱（6549）Profile

TaiwanJ Pharmaceuticals Co., Ltd., a specialty pharmaceutical company, develops and commercializes small molecules for chronic organ inflammation of metabolic, autoimmune, and infectious etiologies in Taiwan. The company also develops JKB-122 and JKB-121; and novel chemical entities for therapy to address chronic liver diseases and allergy/asthma. Its products target various diseases that include liver inflammation/liver fibrosis, non-alcoholic steatohepatitis, non-alcoholic fatty liver disease, autoimmune diseases, asthma, and atopic dermatitis. The company was incorporated in 2011 and is based in Zhubei, Taiwan.

景凱（6549）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.66
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
27.62
PB Ratio
7.61
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-124.83%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
100.00%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.66
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
27.62
PB Ratio
7.61
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-124.83%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
100.00%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
default symbol

6549

景凱

7.84D

-1.91%

(-0.02)

  • When is 6549's latest earnings report released?

    The most recent financial report for 景凱 (6549) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 6549's short-term business performance and financial health. For the latest updates on 6549's earnings releases, visit this page regularly.

  • How much cash does 6549 have?

    At the end of the period, 景凱 (6549) held Total Cash and Cash Equivalents of 33.42M, accounting for 0.38 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is 6549's EPS continuing to grow?

    According to the past four quarterly reports, 景凱 (6549)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.16. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of 6549?

    景凱 (6549)'s Free Cash Flow (FCF) for the period is 453K, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 79.05% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.